Last Updated : July 24, 2024
Details
Generic Name:
olaparib
Project Status:
Not filed
Therapeutic Area:
Breast Cancer
Manufacturer:
AstraZeneca Canada
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
NS0013-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Treatment of adult patients with deleterious or suspected deleterious germline BRCAmutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024